A fusion peptide in preS1 and the human protein-disulfide isomerase ERp57 are involved in HBV membrane fusion process

  1. Jimena Pérez-Vargas
  2. Elin Teppa
  3. Fouzia Amirache
  4. Bertrand Boson
  5. Rémi Pereira de Oliveira
  6. Christophe Combet
  7. Anja Böckmann
  8. Floriane Fusil
  9. Natalia Freitas  Is a corresponding author
  10. Alessandra Carbone  Is a corresponding author
  11. François-Loïc Cosset  Is a corresponding author
  1. École normale supérieure de Lyon, France
  2. Sorbonne Université, France
  3. Centre International de Recherche en Infectiologie, France
  4. Cancer Research Center of Lyon (CRCL), France
  5. University of Lyon, France
  6. Sorbonne Universités, UPMC Univ. Paris 06, France

Abstract

Cell entry of enveloped viruses relies on the fusion between the viral and plasma or endosomal membranes, through a mechanism that is triggered by a cellular signal. Here we used a combination of computational and experimental approaches to unravel the main determinants of hepatitis B virus (HBV) membrane fusion process. We discovered that ERp57 is a host factor critically involved in triggering HBV fusion and infection. Then, through modelling approaches, we uncovered a putative allosteric cross-strand disulfide (CSD) bond in the HBV S glycoprotein and we demonstrate that its stabilization could prevent membrane fusion. Finally, we identified and characterized a potential fusion peptide in the preS1 domain of the HBV L glycoprotein. These results underscore a membrane fusion mechanism that could be triggered by ERp57, allowing a thiol/disulfide exchange reaction to occur and regulate isomerization of a critical CSD, which ultimately leads to the exposition of the fusion peptide.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for figures 1-3, 5-7 and 9.

Article and author information

Author details

  1. Jimena Pérez-Vargas

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Elin Teppa

    UMR 7238, Biologie Computationnelle et Quantitative, Sorbonne Université, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Fouzia Amirache

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Bertrand Boson

    Centre International de Recherche en Infectiologie, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Rémi Pereira de Oliveira

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Christophe Combet

    U1052, Cancer Research Center of Lyon (CRCL), Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7348-3520
  7. Anja Böckmann

    Molecular Microbiology and Structural Biochemistry, University of Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8149-7941
  8. Floriane Fusil

    École normale supérieure de Lyon, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Natalia Freitas

    École normale supérieure de Lyon, Lyon, France
    For correspondence
    natalia.bezerra-de-freitas@ens-lyon.fr
    Competing interests
    The authors declare that no competing interests exist.
  10. Alessandra Carbone

    UMR 7238, Biologie Computationnelle et Quantitative, Sorbonne Universités, UPMC Univ. Paris 06, Paris, France
    For correspondence
    Alessandra.Carbone@lip6.fr
    Competing interests
    The authors declare that no competing interests exist.
  11. François-Loïc Cosset

    École normale supérieure de Lyon, Lyon, France
    For correspondence
    flcosset@ens-lyon.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8842-3726

Funding

ANRS (ECTZ160643)

  • François-Loïc Cosset

ANR (ANR-11-LABX-0048)

  • François-Loïc Cosset

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were performed in accordance with the European Union guidelines for approval of the protocols by the local ethics committee (Authorization Agreement C2EA-15, "Comité Rhône-Alpes d'Ethique pour l'Expérimentation Animale", Lyon, France - APAFIS#27316-2020060810332115 v4).

Copyright

© 2021, Pérez-Vargas et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,926
    views
  • 326
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jimena Pérez-Vargas
  2. Elin Teppa
  3. Fouzia Amirache
  4. Bertrand Boson
  5. Rémi Pereira de Oliveira
  6. Christophe Combet
  7. Anja Böckmann
  8. Floriane Fusil
  9. Natalia Freitas
  10. Alessandra Carbone
  11. François-Loïc Cosset
(2021)
A fusion peptide in preS1 and the human protein-disulfide isomerase ERp57 are involved in HBV membrane fusion process
eLife 10:e64507.
https://doi.org/10.7554/eLife.64507

Share this article

https://doi.org/10.7554/eLife.64507

Further reading

    1. Computational and Systems Biology
    2. Microbiology and Infectious Disease
    Gaetan De Waele, Gerben Menschaert, Willem Waegeman
    Research Article

    Timely and effective use of antimicrobial drugs can improve patient outcomes, as well as help safeguard against resistance development. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is currently routinely used in clinical diagnostics for rapid species identification. Mining additional data from said spectra in the form of antimicrobial resistance (AMR) profiles is, therefore, highly promising. Such AMR profiles could serve as a drop-in solution for drastically improving treatment efficiency, effectiveness, and costs. This study endeavors to develop the first machine learning models capable of predicting AMR profiles for the whole repertoire of species and drugs encountered in clinical microbiology. The resulting models can be interpreted as drug recommender systems for infectious diseases. We find that our dual-branch method delivers considerably higher performance compared to previous approaches. In addition, experiments show that the models can be efficiently fine-tuned to data from other clinical laboratories. MALDI-TOF-based AMR recommender systems can, hence, greatly extend the value of MALDI-TOF MS for clinical diagnostics. All code supporting this study is distributed on PyPI and is packaged at https://github.com/gdewael/maldi-nn.

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Sanjarbek Hudaiberdiev, Ivan Ovcharenko
    Research Article

    Enhancers and promoters are classically considered to be bound by a small set of transcription factors (TFs) in a sequence-specific manner. This assumption has come under increasing skepticism as the datasets of ChIP-seq assays of TFs have expanded. In particular, high-occupancy target (HOT) loci attract hundreds of TFs with often no detectable correlation between ChIP-seq peaks and DNA-binding motif presence. Here, we used a set of 1003 TF ChIP-seq datasets (HepG2, K562, H1) to analyze the patterns of ChIP-seq peak co-occurrence in combination with functional genomics datasets. We identified 43,891 HOT loci forming at the promoter (53%) and enhancer (47%) regions. HOT promoters regulate housekeeping genes, whereas HOT enhancers are involved in tissue-specific process regulation. HOT loci form the foundation of human super-enhancers and evolve under strong negative selection, with some of these loci being located in ultraconserved regions. Sequence-based classification analysis of HOT loci suggested that their formation is driven by the sequence features, and the density of mapped ChIP-seq peaks across TF-bound loci correlates with sequence features and the expression level of flanking genes. Based on the affinities to bind to promoters and enhancers we detected five distinct clusters of TFs that form the core of the HOT loci. We report an abundance of HOT loci in the human genome and a commitment of 51% of all TF ChIP-seq binding events to HOT locus formation thus challenging the classical model of enhancer activity and propose a model of HOT locus formation based on the existence of large transcriptional condensates.